Design Therapeutics Inc Total Liabilities
Design Therapeutics Inc total liabilities. Based on the latest financial reports, Design Therapeutics Inc (DSGN) has total liabilities worth $12.05 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See DSGN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Design Therapeutics Inc (2019–2024)
Total liabilities of Design Therapeutics Inc from 2019 to 2024. This chart illustrates how Design Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check DSGN financial resilience to evaluate the company's liquid asset resilience ratio.
Design Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Design Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blue Moon Zinc Corp
V:MOON
|
Canada | CA$39.66 Million |
|
Bénéteau S.A.
PA:BEN
|
France | €708.79 Million |
|
Citra Putra Realty Tbk PT
JK:CLAY
|
Indonesia | Rp529.29 Billion |
|
Better Home & Finance Holding Company
NYSE:BETR
|
USA | $1.16 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥133.33 Million |
|
Hangzhou Century Co Ltd
SHE:300078
|
China | CN¥423.90 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$40.23 Million |
|
Shenzhen Jiawei Photovoltaic Lighting Co Ltd
SHE:300317
|
China | CN¥1.48 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Design Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Design Therapeutics Inc.
Liquidity & Leverage Metrics
Design Therapeutics Inc Total Liabilities Ratios Explained
Design Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Design Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Design Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Design Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.00 Million | -16.39% |
| 2023-12-31 | $11.96 Million | -13.53% |
| 2022-12-31 | $13.83 Million | +64.08% |
| 2021-12-31 | $8.43 Million | -82.38% |
| 2020-12-31 | $47.83 Million | +1181.65% |
| 2019-12-31 | $3.73 Million | -- |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more